Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

>

19,795,84519,613,006Property and equipment, net

483,976788,666Other long-term assets and deferred costs

113,13053,384Goodwill

2,348,4532,348,453Total assets

$   22,741,404$   22,803,509LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
,697,280$
,445,700Accrued expenses and other liabilities

2,328,8772,655,330Deferred revenue

1,381,755514,312Current portion of long-term debt

749,997-Short-term debt

1,330,507-Total current liabilities

7,488,4164,615,342Other long-term liabilities

579,427449,709Long-term debt, less current portion

1,704,108-Derivative instruments

1,295,6131,886,652Total liabilities

11,067,5646,951,703Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,352,651 and 48,236,172 shares issued and outstanding at December 31, 2012 and 2011, respectively

4,8354,824Additional paid-in-capital

210,495,905208,525,917Accumulated other comprehensive (loss) income

(217,328)1,010,522Accumulated deficit

(198,609,572)(193,689,457)Total stockholders' equity

11,673,84015,851,806Total liabilities and stockholders' equity

$  22,741,404$  22,803,509 PHARMATHENE, INC.CONSOLIDATED STATEMENTS OF OPERATIONSYear Ended December 31,20122011Revenue

$ 25,175,887$  24,266,274Operating expenses:Research and development

19,509,62921,219,853General and administrative

11,628,73214,311,079Depreciation and amortization

303,916461,073Total operating expenses

31,442,27735,992,005Loss from operations

$ (6,266,390)$ (11,725,731)Other income (expense):Interest income

17,80816,660Interest expense

(342,561)(54,573)Gain on the sale of assets held for sale

-781,760Realization of cumulative translation adjustment 

1,227,656-Chan
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015 Synthetic Biologics, ... therapies for serious infections and diseases, with a ... clinical data supporting the development of SYN-004, the ... intravenous (IV) antibiotics within the gastrointestinal (GI) tract ... microbiome for the prevention of C. difficile ...
(Date:4/1/2015)... Earlier this year, A.J. O’Connor ... industry association that represents research-based life science organizations in ... Parker, AJO’s Vice President of Business Development & Executive ... event that attracted over 750 attendees. , In ... year old cancer survivor shared his moving story of ...
(Date:3/31/2015)... and VANCOUVER , March 31, 2015 ... EPI) announced today that it has filed with the ... Investigation New Drug ("IND") application related to the Company,s ... Approval of the IND application is required in order ... the US.  The IND application is ...
(Date:3/31/2015)... 2015  Bayer HealthCare (Bayer) has expanded its ... of Technology (MIT) and Harvard University to include ... this new part of the alliance is to ... new cardiovascular therapies. "We are excited ... to the area of cardiovascular genomics to discover ...
Breaking Biology Technology:Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 2Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 3Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015 4HR Consulting Firm, A.J. O'Connor Associates Joins BioNJ – The Vibrant 400 Member Strong Life Sciences Industry Association - and Attends its Annual Dinner 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 2ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 3ESSA Pharma Inc. Announces Filing of Investigational New Drug Application for EPI-506 4Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 2Bayer HealthCare Expands Collaboration with Broad Institute of MIT and Harvard to Develop Therapies for Cardiovascular Disease 3
... Israel, December 2 InSightec Ltd. announced,today that ... with the ExAblate(R) system has the potential to ... have spread to,the bones (bone metastases). The results ... 11 online issue of Annals of Surgical Oncology, ...
... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
... BASKING RIDGE, N.J., Dec. 2 Regado Biosciences, Inc., ... newly created position of Senior Vice President of Business ... McDonald brings to Regado nearly 20 years of experience ... operations, portfolio management and marketing. She will report ...
Cached Biology Technology:New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2
(Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
(Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
... to humans, the bacteria and tiny plants living in the ... is quite different than ours for one, they can,t ... red meat for a pick-me-up. So where does their ... " points to a source on the seafloor: minute particles ...
... a specific sugar residue on the cell surface, which is ... Faissner has now been able to use LewisX for the ... researchers report on their results in the Journal of ... Antibodies that recognise the LewisX sugar residue are used routinely ...
Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2As good as gold 2
Phospho-Chk1 (Ser296) Antibody Shipping Temperature: HOT Storage Temperature: -20C...
...
3M Imidazole Solution 125 ml...
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Biology Products: